Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Somatostatinoma 1Ovarian Neoplasms 1Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Leucovorin 4Everolimus 4Fluorouracil 3Bevacizumab 3vatalanib 2pentetreotide 2Trastuzumab 2Sunitinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Cisplatin 2Bortezomib 2Biological Therapy 2veliparib 1tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Cytidine Triphosphate × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡